Common variable immunodeficiency is best described as which of the following?

Study for the NBME Immunology Test. Study with flashcards and multiple choice questions, each question includes hints and explanations. Prepare to excel!

Multiple Choice

Common variable immunodeficiency is best described as which of the following?

Explanation:
Common variable immunodeficiency represents a defect in B cell maturation and antibody production, leading to low levels of immunoglobulins—especially IgG—with poor antibody responses to vaccines. This results in recurrent bacterial infections, particularly of the sinopulmonary tract, often beginning in adolescence or adulthood. The hallmark is hypogammaglobulinemia with impaired specific antibody production, while T-cell function is typically preserved. This differs from hyper-IgM syndrome, where class-switching from IgM to other isotypes is defective, leading to normal or high IgM with low IgG/IgA/IgM; from severe combined immunodeficiency, which involves profound defects in both T and B cell immunity presenting early in infancy; and from IgA deficiency, which is mainly a selective loss of IgA with generally normal IgG and fewer systemic antibody-production issues.

Common variable immunodeficiency represents a defect in B cell maturation and antibody production, leading to low levels of immunoglobulins—especially IgG—with poor antibody responses to vaccines. This results in recurrent bacterial infections, particularly of the sinopulmonary tract, often beginning in adolescence or adulthood. The hallmark is hypogammaglobulinemia with impaired specific antibody production, while T-cell function is typically preserved.

This differs from hyper-IgM syndrome, where class-switching from IgM to other isotypes is defective, leading to normal or high IgM with low IgG/IgA/IgM; from severe combined immunodeficiency, which involves profound defects in both T and B cell immunity presenting early in infancy; and from IgA deficiency, which is mainly a selective loss of IgA with generally normal IgG and fewer systemic antibody-production issues.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy